FORMAL PROTEST OF PENTERRA PHARMACEUTICALS CORP.
Prepared by: Garrett Simmons and Leila Nazari, Calderwood & Harkness LLP Reviewed by: Leonard Cross, Sylvia Hartwell C&H Matter Number: 1018-00009
Right-click to update Table of Contents
I. INTRODUCTORY STATEMENT AND IDENTIFICATION
1.1 Taxpayer Identification
The taxpayer filing this Formal Protest is Penterra Pharmaceuticals Corp. ("PPC" or the "Company"), a corporation organized and existing under the laws of the State of Delaware, with its principal place of business located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550.
PPC's Employer Identification Number ("EIN") is 22-3741856. PPC is a publicly traded corporation whose common stock is listed on the Nasdaq Stock Market under the ticker symbol "PPCA." PPC's fiscal year-end is December 31 of each calendar year.
The federal income tax returns at issue in this Protest are United States Corporation Income Tax Returns (Forms 1120) filed by PPC for the taxable years ending December 31, 2017, December 31, 2018, December 31, 2019, and December 31, 2020 (collectively, the "Tax Years at Issue" or "TY 2017–2020"). PPC was not a participant in the Compliance Assurance Process ("CAP") administered by the Internal Revenue Service ("IRS" or the "Service") for any of the Tax Years at Issue.
1.2 Statement of Intent
Penterra Pharmaceuticals Corp. hereby formally protests the proposed adjustments set forth in the Notice of Proposed Adjustment ("NOPA") dated October 12, 2023, and the 30-Day Letter (Letter 950-E) dated November 8, 2023, both issued by the IRS Large Business & International Division ("LB&I"), Exam Team LB&I-NE-TP-2022-00641, with respect to PPC's federal income tax returns for TY 2017–2020. PPC disputes each proposed adjustment as set forth more fully herein.
PPC respectfully requests, pursuant to Revenue Procedure 2015-41 and the provisions of the Internal Revenue Manual, a conference with the IRS Independent Office of Appeals ("Appeals") to resolve the disputed issues. PPC understands that the 30-Day Letter requires a response within 30 days of issuance, and that the original deadline was December 8, 2023. PPC further notes that IRS Supervisory Revenue Agent Gerald Meskill agreed, on behalf of the Exam Team, to extend the deadline for filing this Protest to December 22, 2023. This Protest is being timely filed within the extended period.
1.3 Authorized Representatives
PPC is represented in this matter by Calderwood & Harkness LLP ("C&H"), a national law firm with its lead office for this engagement located at 1735 Market Street, Suite 3100, Philadelphia, Pennsylvania 19103, and its firm headquarters located at 600 Lexington Avenue, New York, New York 10022.
The following individuals are authorized to represent PPC before the IRS in connection with the matters addressed in this Protest, as set forth in IRS Form 2848 (Power of Attorney and Declaration of Representative) filed on June 8, 2022, copies of which are on file with the Exam Team:
Leonard Cross — Responsible Partner, Tax Department, Calderwood & Harkness LLP
Sylvia Hartwell — Billing Partner, Tax Department, Calderwood & Harkness LLP
Garrett Simmons — Lead Associate, Tax Department, Calderwood & Harkness LLP
Leila Nazari — Working Associate, Tax Department, Calderwood & Harkness LLP
All of the above-named representatives are licensed to practice before the Internal Revenue Service and are admitted to practice law in one or more U.S. jurisdictions. C&H reserves the right to supplement or amend the list of authorized representatives as the matter progresses.
1.4 Summary of Proposed Adjustments Being Protested
The IRS has proposed a total net adjustment of $380,400,000 to PPC's taxable income across TY 2017–2020. The proposed adjustments, which PPC protests in their entirety, consist of the following components:
In addition to the proposed income adjustments, the IRS has proposed a penalty under Internal Revenue Code ("IRC" or "Code") § 6662(e) in the amount of approximately $15,977,000, representing a 20% substantial valuation misstatement penalty applied to the underpayment of tax attributable to the net § 482 allocation (computed as $380,400,000 × 21% × 20% = approximately $15,977,000). The IRS reserved, but did not assert, the IRC § 6662(h) gross valuation misstatement penalty of 40%.
PPC disputes each proposed adjustment in its entirety and asserts that its transfer pricing methodologies for both the cost-sharing arrangement and the legacy IP royalty arrangement comply fully with the arm's-length standard under IRC § 482 and the applicable Treasury Regulations. PPC further contends that the proposed penalty under IRC § 6662(e) is without merit and should be fully abated, as PPC maintained contemporaneous transfer pricing documentation satisfying all applicable requirements and had reasonable cause for its reported positions.
II. STATEMENT OF FACTS
2.1 Corporate Overview
Penterra Pharmaceuticals Corp. is a specialty pharmaceutical and biotechnology company engaged in the research, development, manufacture, and commercialization of pharmaceutical products. PPC's therapeutic areas of focus are oncology, immunology, and rare-disease therapeutics. The Company has been at the forefront of biologic drug development in these fields for over two decades and maintains a robust pipeline of clinical-stage and commercial-stage compounds.
PPC is headquartered in Princeton Junction, New Jersey, where it maintains its corporate offices, its primary U.S. research and development facilities, and certain of its commercial operations. As of the end of fiscal year 2020, PPC employed approximately 14,500 individuals globally, with the majority of its workforce located in the United States.
For fiscal year 2020, PPC reported total annual revenue of approximately $6.82 billion and pre-tax income of approximately $1.47 billion. PPC is and has been a significant taxpayer for all of the Tax Years at Issue.
During the Tax Years at Issue, the key officers of PPC included:
• Catherine Falk — Chief Executive Officer
• Rajesh Iyer — Chief Financial Officer
• Deborah Staines — General Counsel
• Marcus Whitfield — Vice President, Global Tax
Each of these officers served in their respective capacities throughout the entirety of TY 2017–2020, providing continuity and stability in the Company's governance and decision-making processes during the period at issue.
2.2 Corporate Structure
PPC's relevant corporate structure for purposes of this Protest is as follows:
Penterra Pharmaceuticals Corp. ("PPC") is the ultimate U.S. parent corporation and is organized under the laws of Delaware. PPC is the 100% owner of Penterra Holdings Luxembourg S.à r.l. ("PHL"), a société à responsabilité limitée organized under the laws of the Grand Duchy of Luxembourg (RCS Number B 168452), registered at 14, rue Aldringen, L-1118 Luxembourg. PHL is treated as a disregarded entity for United States federal income tax purposes under the entity classification regulations (Treas. Reg. § 301.7701-3).
PHL, in turn, is the 100% owner of Penterra Biopharma International DAC ("PBI"), a Designated Activity Company organized under the laws of Ireland (Irish Tax Reference 3218764T), registered at 4th Floor, Claremont House, Sandyford Business Park, Dublin D18 K7T4, Ireland. PBI is treated as a controlled foreign corporation ("CFC") for United States federal income tax purposes.
PBI is the 100% owner of Penterra Manufacturing Ireland Ltd. ("PMI"), an Irish private limited company (Companies Registration Office Number 512347), registered at Unit 7, Ringaskiddy Industrial Estate, Co. Cork T12 PX29, Ireland. PMI operates as a contract manufacturer of PPC's pharmaceutical products for non-Americas markets, as described further in Section 2.4 below.
In summary, the ownership chain is: PPC (Delaware) → PHL (Luxembourg, disregarded entity) → PBI (Ireland, CFC) → PMI (Ireland). A detailed organizational chart depicting this structure, including entity types, jurisdictions of organization, and registered offices, will be attached as Exhibit A.
2.3 PBI — Establishment and Functions
PBI was incorporated on March 15, 2012, as part of PPC's strategic initiative to build a robust international operating platform for the commercialization of its pharmaceutical products outside the Americas (defined for purposes of PPC's intercompany arrangements as North America, Central America, South America, and the Caribbean, collectively the "Americas"). PBI serves as the intellectual property holding company and the principal entity responsible for the commercialization of PPC's products in all territories outside the Americas (the "non-Americas" territory or the "Rest of World").
PBI is not a shell holding company. From its inception, PBI has been structured as a substantive operating entity with genuine commercial functions, meaningful decision-making authority, and significant human and capital resources. PBI manages contract manufacturing arrangements (through its subsidiary PMI, as described below) and oversees distribution arrangements across the Europe, Middle East, and Africa ("EMEA") and Asia-Pacific ("APAC") regions.
PBI's Managing Director is Aidan Naughton, who has been resident in Dublin, Ireland, since PBI's incorporation and who maintains operational authority over PBI's day-to-day business activities. Mr. Naughton reports to PPC's Chief Executive Officer on matters of corporate strategy but exercises independent judgment and decision-making authority with respect to the commercial operations, pricing, market access, and regulatory affairs of PBI's non-Americas business.
PBI's workforce has grown substantially since its establishment. At the time of its incorporation in 2012, PBI employed 52 individuals. By the end of fiscal year 2020, PBI's headcount had grown to 185 employees, reflecting the organic expansion of PBI's commercial responsibilities and the maturation of its operations. PBI's employees include professionals in regulatory affairs, medical affairs, commercial strategy, supply chain management, finance, legal, and general administration. These employees are based at PBI's offices, which comprise approximately 18,000 square feet of leased office space at Sandyford Business Park, Dublin, Ireland.
PBI's governance is robust and active. During TY 2017–2020, PBI's board of directors held a total of 42 board meetings in Dublin, consisting of regular quarterly meetings and special sessions convened as necessary to address significant business decisions. These board meetings addressed matters including commercial strategy, pricing decisions, new product launches, regulatory submissions, distributor appointments, and capital allocation.
PBI's functions and activities during the Tax Years at Issue included, among other things:
(a) Co-funding of PPC's global research and development activities through cost-sharing payments under the CSA, as described in Section 2.6 below;
(b) Cumulative regulatory expenditures of approximately €47.2 million during TY 2017–2020 for regulatory submissions and marketing authorization applications across the non-Americas territory;
(c) Independent pricing decisions across 68 country markets in the EMEA and APAC regions, reflecting PBI's analysis of local market conditions, competitive dynamics, reimbursement frameworks, and regulatory requirements;
(d) Assumption of market risk for the non-Americas territories, including the risks associated with product demand, competitive entry, pricing pressures, regulatory changes, and adverse events;
(e) Key commercial decisions including market entry timing, distribution partner selection, launch sequencing, promotional strategy, and commercial resource allocation;
(f) Management of relationships with contract manufacturers (including PMI) and third-party logistics providers for the supply of PPC products in non-Americas markets;
(g) Independent treasury operations and banking through Glenmore Bank Ireland plc, including the maintenance of dedicated operating accounts, intercompany payment flows, and foreign exchange management; and
(h) Oversight of intellectual property protection activities in non-Americas jurisdictions, including patent enforcement, trademark registration, and regulatory data exclusivity management.
PBI's financial performance during the Tax Years at Issue was substantial. For fiscal year 2020, PBI reported revenue of approximately €2.14 billion and pre-tax income of approximately €1.06 billion. PBI claimed Irish Knowledge Development box ("KDB") benefits at an effective rate of 6.25% on from fiscal year 2016 forward, with the standard Irish trading rate of 12.5% applying to the remainder of its income. PBI's tax position in Ireland was supported by compliance with Irish domestic tax law and the applicable provisions of the U.S.-Ireland Income Tax Treaty.
2.4 PMI — Contract Manufacturer
Penterra Manufacturing Ireland Ltd. ("PMI") operates as a contract manufacturer of PPC's oncology and immunology biologics for non-Americas markets. PMI manufactures these products under a contract manufacturing arrangement with PBI, pursuant to which PMI is compensated on a cost-plus basis at a markup of cost plus 8%. This cost-plus markup was established through benchmarking analysis and reflects the arm's-length compensation for a contract manufacturer performing routine manufacturing functions without ownership of the underlying intellectual property.
PMI's manufacturing facility is located at Ringaskiddy Industrial Estate, Co. Cork, Ireland, and employs approximately 620 personnel, including scientists, engineers, quality assurance professionals, and production staff. PMI does not bear significant market risk and does not own or exploit the intellectual property associated with the products it manufactures. PMI's compensation reflects its limited-risk, routine manufacturing profile.
2.5 Key Products
PPC's product portfolio includes three key commercial-stage products that account for the substantial majority of the Company's global revenue:
Veritaxol (oncology): Veritaxol is PPC's blockbuster oncology product and its largest revenue-generating compound. For fiscal year 2020, Veritaxol generated global net sales of approximately $3.12 billion, of which approximately $1.34 billion (roughly 43%) was attributable to non-Americas markets. Veritaxol is approved for multiple oncology indications and is marketed in over 80 countries worldwide.
Imvara (immunology): Imvara is PPC's leading immunology product. For fiscal year 2020, Imvara generated global net sales of approximately $1.87 billion, of which approximately $0.79 billion (roughly 42%) was attributable to non-Americas markets. Imvara is approved for several autoimmune and inflammatory conditions and is marketed across major global markets.
Cerulon (rare disease): Cerulon is PPC's rare-disease therapeutic. For fiscal year 2020, Cerulon generated global net sales of approximately $0.62 billion, of which approximately $0.28 billion (roughly 45%) was attributable to non-Americas markets. Cerulon serves patients with an orphan-designated condition and benefits from regulatory exclusivity protections in multiple jurisdictions.
Together, these three products represent the core of PPC's commercial portfolio and are the principal revenue-generating assets covered by the CSA and legacy IP licensing arrangements at issue in this Protest.
2.6 The Cost-Sharing Arrangement
PPC and PBI entered into a Cost-Sharing Arrangement ("CSA"), effective July 1, 2012, governing the co-development and exploitation of PPC's pharmaceutical intellectual property portfolio. The CSA was structured as a qualified cost-sharing arrangement under Treasury Regulation § 1.482-7 and was designed to allocate the costs and risks of intangible development activities between PPC and PBI in proportion to their reasonably anticipated benefits from the exploitation of the resulting intellectual property.
Under the CSA, PBI acquired the right to develop and exploit PPC's pharmaceutical IP portfolio outside the Americas territory, while PPC retained the corresponding rights for the Americas territory. The scope of the CSA encompassed both existing and future intangible development activities relating to PPC's oncology, immunology, and rare-disease therapeutic compounds.
In connection with the execution of the CSA, PBI made a platform contribution transaction ("PCT") payment of $312 million as a lump sum to PPC on July 1, 2012. This PCT payment represented PBI's buy-in to PPC's pre-existing intellectual property, which at that time consisted primarily of clinical-stage and approved oncology compounds (including early-stage Veritaxol and its predecessor compounds). The PCT was valued using an income method consistent with the requirements of Treas. Reg. § 1.482-7(g), as described further in Section IV below.
Following the execution of the CSA, PBI made ongoing cost-sharing payments to PPC each year, calculated as PBI's proportionate share of total qualified research and development costs incurred in connection with intangible development activities covered by the CSA. PBI's cost-sharing percentages were determined based on projected revenue splits between PPC's Americas territory and PBI's non-Americas territory, reflecting the reasonably anticipated benefits ("RAB") methodology prescribed by Treas. Reg. § 1.482-7(e).
PBI's cost-sharing percentages and corresponding payments for TY 2017–2020 were as follows:
The gradual increase in PBI's cost-sharing percentage from 38.2% in 2017 to 42.7% in 2020 reflects the growing share of non-Americas revenue in PPC's global revenue mix, which in turn reflects PBI's expanding commercial operations, successful market development efforts, and increasing patient access in EMEA and APAC markets.
The CSA was structured and documented to comply with all applicable requirements of Treas. Reg. § 1.482-7, including, without limitation, the requirements for controlled participant eligibility, the identification of intangible development activities, the RAB-based cost-sharing methodology, and the PCT payment. A summary of the principal terms of the CSA will be attached as Exhibit B.
2.7 The Legacy IP Royalty Arrangement
Separately from the CSA, PBI licensed from PPC certain legacy pharmaceutical compounds that were not covered by the CSA. These legacy compounds predated the execution of the CSA (i.e., they were of pre-2012 vintage) and were subject to a separate intercompany licensing arrangement. Under this arrangement, PBI paid PPC a royalty at a rate of 4.5% of net sales for the commercialization of the legacy compounds in the non-Americas territory.
The legacy compound non-Americas net sales and corresponding royalty payments for TY 2017–2020 were as follows:
The declining trajectory of the legacy compound net sales — from $814.6 million in 2017 to $624.1 million in 2020 — reflects the normal product lifecycle dynamics affecting these older compounds, including loss of exclusivity, generic competition, and market share erosion. The 4.5% royalty rate was established through benchmarking analysis and reflects the arm's-length compensation for the licensing of mature pharmaceutical compounds with declining commercial value, as described further in Section V below.
2.8 Contemporaneous Transfer Pricing Documentation
PPC maintained contemporaneous transfer pricing documentation for all four Tax Years at Issue, prepared in accordance with the penalty protection standards set forth in IRC § 6662(e) and Treasury Regulation § 1.6662-6. This documentation was prepared by Crestfield & Associates LLP ("Crestfield"), PPC's independent auditor and tax return preparer, under the direction of Martin Ogilvy (Engagement Partner) and Susan Lam (Transfer Pricing Partner).
The contemporaneous documentation established and supported the CSA cost-sharing methodology under Treas. Reg. § 1.482-7 and the legacy IP royalty methodology under Treas. Reg. § 1.482-4. The documentation included, among other things, functional analyses, economic analyses, benchmarking studies, best method selection analyses, and descriptions of the controlled transactions and the methodologies applied. The documentation was in existence at the time each return was filed and satisfies the contemporaneous documentation requirements of the applicable regulations.
2.9 The IRS Examination
The IRS opened an examination of PPC's federal income tax returns for TY 2017–2020 on May 16, 2022, as evidenced by Letter 2205-A issued on that date. The examination has been conducted by the IRS Large Business & International Division, Exam Team LB&I-NE-TP-2022-00641.
The key members of the IRS Exam Team are:
• Gerald Meskill — Supervisory Revenue Agent / Team Manager
• Patricia Dunleavy — Lead Revenue Agent
• Dr. Alan Washburne — IRS Economist, Transfer Pricing Practice
• Franklin Rosario — Attorney-Advisor, IRS Office of Chief Counsel
• Donna Hirabayashi — Senior Counsel, IRS Office of Chief Counsel
During the course of the examination, the IRS issued a total of 47 Information Document Requests ("IDRs") between June 2022 and September 2023. PPC cooperated fully with the examination and responded to each IDR in a timely manner, producing voluminous documents, data, and analyses requested by the Exam Team.
On October 12, 2023, the IRS issued the NOPA for all four Tax Years at Issue, proposing the adjustments described in Section III below. On November 8, 2023, the IRS issued the 30-Day Letter (Letter 950-E) to PPC, providing PPC with the opportunity to file a formal protest and request an Appeals conference. As noted above, IRS Supervisory Revenue Agent Gerald Meskill agreed to extend the deadline for filing this Protest to December 22, 2023.
III. SUMMARY OF IRS PROPOSED ADJUSTMENTS
3.1 CSA Cost-Sharing Ratio Adjustments ($235,010,000)
The IRS proposes to increase PBI's cost-sharing percentage under the CSA by approximately 8 to 12 percentage points for each of the Tax Years at Issue. The IRS asserts that PPC's projections of reasonably anticipated benefits used to determine the cost-sharing ratios understated the value of PPC's U.S.-based contributions to intangible development and, correspondingly, overstated the share of benefits anticipated by PBI relative to the actual value PBI received.
The IRS's proposed year-by-year adjustments to the CSA cost-sharing ratios are as follows:
The total CSA cost-sharing ratio adjustment is approximately $235,010,000 (as rounded by the Exam Team in the NOPA).
PPC disputes these adjustments in their entirety. PPC's cost-sharing ratios were based on contemporaneous, reasonable projections of anticipated benefits and complied fully with the RAB methodology prescribed by Treas. Reg. § 1.482-7(e). The legal and economic bases for PPC's position are set forth in Section IV below.
3.2 Royalty Rate Adjustments ($188,040,000)
The IRS proposes to increase the royalty rate on the legacy IP license from 4.5% to 11.0% of net sales for the non-Americas territory. The IRS bases its proposed rate on a comparable uncontrolled transaction ("CUT") analysis using third-party pharmaceutical licensing agreements that, according to the IRS, are comparable to the PPC-PBI legacy IP license.
The IRS's proposed year-by-year adjustments to the legacy IP royalty rate are as follows:
The total royalty rate adjustment is approximately $188,040,000 (as rounded by the Exam Team in the NOPA).
PPC disputes these adjustments in their entirety. PPC's 4.5% royalty rate falls squarely within the arm's-length range established by properly selected CUT comparables and reflects the declining value of the underlying legacy IP. The legal and economic bases for PPC's position are set forth in Section V below.
3.3 Correlative Offset (−$42,650,000)
The IRS allowed a correlative offset of $42,650,000 in calculating the net proposed adjustment in order to avoid double-counting between the CSA cost-sharing ratio adjustments and the royalty rate adjustments. This offset reflects the IRS's acknowledgment that certain income attributed to PPC through the increased cost-sharing ratios overlaps, to some extent, with income attributed to PPC through the increased royalty rate. PPC accepts the mathematical appropriateness of this correlative offset to the extent that any adjustment were to be sustained, but PPC disputes the underlying adjustments that give rise to the need for such an offset. The correlative offset is discussed further in Section X below.
3.4 Net Proposed Adjustment
The IRS's total net proposed adjustment to PPC's taxable income for TY 2017–2020 is calculated as follows:
CSA cost-sharing ratio adjustments: $235,010,000
Plus: Royalty rate adjustments: $188,040,000
Less: Correlative offset: ($42,650,000)
Net proposed adjustment: $380,400,000
3.5 PCT Undervaluation Assertion (Background)
As background to the proposed adjustments, the NOPA reflects the IRS's assertion that the $312 million PCT payment made by PBI to PPC on July 1, 2012, undervalued the pre-existing intellectual property that PBI acquired rights to exploit. Specifically, IRS Economist Dr. Alan Washburne, using an income method with a weighted average cost of capital ("WACC") discount rate of 7.2% and different revenue projections than those used by PPC, valued the PCT at approximately $852 million — implying that PBI underpaid by approximately $540 million.
However, because the 2012 taxable year is not within the scope of the current examination and is outside the applicable statute of limitations, the IRS did not propose a direct adjustment to the 2012 PCT payment. Instead, the IRS sought to accomplish a comparable economic result by recharacterizing the ongoing CSA cost-sharing ratios and the legacy IP royalty rates for TY 2017–2020 as failing to reflect the full value of the intellectual property contributed by PPC to the arrangement. The effect of this approach is to attribute additional income to PPC in TY 2017–2020 as a surrogate for what the IRS believes was an underpayment at the inception of the CSA.
PPC disputes the IRS's PCT valuation and contends that the $312 million PCT payment was within the arm's-length range, as set forth in Section IV.5 below. PPC further contends that the IRS's approach of inflating the ongoing cost-sharing ratios to compensate for a perceived PCT undervaluation improperly conflates two distinct transfer pricing issues.
3.6 Economic Substance Challenge
In the NOPA, the IRS also asserted that PBI lacked sufficient economic substance to justify its role as the IP owner and CSA participant for the non-Americas territory. Specifically, the IRS argued that key DEMPE functions — Development, Enhancement, Maintenance, Protection, and Exploitation of the intangible assets — remained in the United States and were performed by PPC's U.S.-based personnel, with PBI serving primarily as a conduit for the allocation of income to a lower-tax jurisdiction.
PPC vigorously disputes this characterization. PBI possesses robust economic substance and performs meaningful DEMPE functions commensurate with its role as IP exploiter and CSA participant for the non-Americas territory, as set forth in detail in Section VI below.
3.7 Proposed Penalty
The IRS proposes a penalty under IRC § 6662(e) for substantial valuation misstatement in the transfer pricing context. The penalty is calculated at 20% of the underpayment of tax attributable to the net § 482 allocation:
Net proposed adjustment: $380,400,000
Tax at 21% corporate rate: $79,884,000
Penalty at 20%: $15,977,000 (approximately $15.98 million)
The IRS reserved the right to assert, but did not assert, the IRC § 6662(h) gross valuation misstatement penalty at the 40% rate.
PPC disputes the proposed penalty in its entirety. PPC maintained contemporaneous transfer pricing documentation that satisfies the requirements of IRC § 6662(e)(3)(B) and Treas. Reg. § 1.6662-6, and PPC had reasonable cause for its reported transfer pricing positions. The legal and factual bases for PPC's penalty defense are set forth in Section VII below.
IV. LAW AND ARGUMENT — CSA COST-SHARING RATIO
4.1 Legal Framework
Section 482 of the Internal Revenue Code grants the Secretary of the Treasury the authority to distribute, apportion, or allocate gross income, deductions, credits, or allowances among organizations, trades, or businesses owned or controlled by the same interests, "if he determines that such distribution, apportionment, or allocation is necessary in order to prevent evasion of taxes or clearly to reflect the income of any such organizations, trades, or businesses." The touchstone of IRC § 482 is the arm's-length standard: controlled transactions must produce results consistent with those that would have been realized if uncontrolled taxpayers had engaged in the same transaction under the same circumstances. See Treas. Reg. § 1.482-1(b)(1).
Treasury Regulation § 1.482-7 provides the detailed rules governing qualified cost-sharing arrangements ("QCSAs"). Under Treas. Reg. § 1.482-7(a), a QCSA is an arrangement between two or more controlled participants to share the costs and risks of developing intangible property in proportion to their reasonably anticipated benefits from the exploitation of such property. The regulations prescribe specific requirements for a valid QCSA, including:
(a) Controlled participant eligibility: Each participant must be a controlled taxpayer that reasonably anticipates benefits from the exploitation of the intangible property. Treas. Reg. § 1.482-7(d)(1).
(b) Intangible development activities: The CSA must relate to the development of specifically identified intangible property through research and development activities. Treas. Reg. § 1.482-7(d)(2).
(c) Reasonably anticipated benefits ("RAB") methodology: The cost-sharing ratios must be determined on the basis of each participant's share of the reasonably anticipated benefits from the exploitation of the intangible property developed under the CSA. Treas. Reg. § 1.482-7(e). Reasonably anticipated benefits must be measured using a basis that is "consistent with the economic substance of the arrangement" and that "reflects the anticipated economic benefits" to each participant. Id.
(d) Platform contribution transactions ("PCTs"): When a participant contributes pre-existing resources, capabilities, or rights to the CSA, a PCT payment is required to compensate the contributor. The PCT payment must reflect the arm's-length value of the pre-existing contributions. Treas. Reg. § 1.482-7(g).
The best method rule, set forth in Treas. Reg. § 1.482-1(d), requires that the method applied to evaluate whether the results of a controlled transaction are consistent with the arm's-length standard be "the method that, under the facts and circumstances, provides the most reliable measure of an arm's-length result." The selection of the best method depends on the degree of comparability between the controlled transaction and any comparable uncontrolled transactions, and the quality of the data and the reliability of the assumptions.
The case law applying these principles further informs the analysis. In Altera Corp. v. Commissioner, 926 F.3d 1061 (9th Cir. 2019), the Ninth Circuit upheld Treasury Regulation § 1.482-7(d)(2) (as redesignated from the prior version of the regulation) requiring that stock-based compensation costs be included in the cost pool shared under a QCSA. While Altera did not directly address cost-sharing ratios, the decision reinforced the principle that the regulations governing QCSAs are entitled to deference when they reflect a reasonable interpretation of the statute.
In Harborview Corporation, Inc. v. Commissioner, T.C. Memo. 2016-112, aff'd in part, vacated in part, and remanded, 900 F.3d 610 (8th Cir. 2018), the Tax Court and the Eighth Circuit addressed transfer pricing methodologies for intercompany royalty arrangements in the context of medical device manufacturing. The Eighth Circuit's decision emphasized the importance of selecting the best method and properly applying comparability factors. While the factual context of Harborview Corporation differs from the present case, the principles articulated therein are instructive regarding the application of the CUT method and the importance of reliable comparable data.
PPC also notes that the OECD Transfer Pricing Guidelines, as revised in 2017 and 2022, provide persuasive (though not binding) authority on the proper treatment of cost-sharing arrangements. Chapter VIII of the OECD Guidelines addresses cost contribution arrangements and provides guidance consistent with the principles of Treas. Reg. § 1.482-7, including the requirement that contributions be proportionate to reasonably expected benefits.
4.2 PPC's Cost-Sharing Ratios Reflect Reasonably Anticipated Benefits
PBI's cost-sharing percentages for TY 2017–2020 — 38.2%, 39.6%, 41.1%, and 42.7%, respectively — were determined in accordance with the RAB methodology prescribed by Treas. Reg. § 1.482-7(e). The cost-sharing ratios were based on projected revenue splits between PPC's Americas territory and PBI's non-Americas territory, which served as a reasonable proxy for the relative anticipated economic benefits to each CSA participant from the exploitation of the intangible property developed under the CSA.
The gradual increase in PBI's cost-sharing percentage from 38.2% in 2017 to 42.7% in 2020 reflects the documented expansion of non-Americas market share over this period. This expansion was driven by PBI's growing commercial infrastructure, successful regulatory approvals and market launches in additional non-Americas country markets, and increasing patient access in EMEA and APAC regions. The upward trajectory of PBI's share is consistent with and directly attributable to PBI's own commercial activities and risk-bearing in the non-Americas territory.
The revenue projections underlying the cost-sharing ratios were prepared contemporaneously each year by PPC's and PBI's respective finance teams, using reasonable assumptions regarding product demand, pricing, market growth, competitive dynamics, and regulatory developments. These projections were reviewed and validated by Crestfield & Associates as part of PPC's annual transfer pricing documentation process. The projections were updated annually to reflect the most current market data and forecasts available at the time, and were not static or formulaic.
The total qualified R&D costs subject to cost-sharing under the CSA for TY 2017–2020 were $487.3 million, $523.8 million, $561.2 million, and $598.4 million, respectively, reflecting PPC's substantial and growing investment in pharmaceutical research and development. PBI's share of these costs — $186.15 million, $207.42 million, $230.65 million, and $255.52 million — was commensurate with PBI's share of reasonably anticipated benefits, as required by the regulations.
PPC's cost-sharing ratios thus properly determined, fully documented, and consistent with the arm's-length standard. No adjustment is warranted.
4.3 Rebuttal of IRS's Proposed Percentages
The IRS's proposed cost-sharing percentages — 48.2%, 50.6%, 52.3%, and 53.7% for TY 2017 through 2020, respectively — are not supported by reasonable projections of anticipated benefits and should be rejected for several independent reasons.
First, the IRS's proposed percentages overstate the value attributable to U.S.-source contributions by failing to account for PBI's growing commercial infrastructure, market development activities, and risk assumption in the non-Americas territories. The IRS's projections appear to assume that PPC's U.S.-based R&D activities generate a disproportionate share of the anticipated benefits, without adequately recognizing the substantial contributions that PBI makes to the commercial success of PPC's products outside the Americas. PBI's regulatory expenditures, pricing decisions, market access activities, and distribution management are integral to the realization of non-Americas revenue, and the IRS's failure to account for these contributions produces inflated cost-sharing percentages that do not reflect economic reality.
Second, the IRS's approach improperly seeks to compensate for its disagreement with the PCT valuation through adjustments to the ongoing cost-sharing ratios. As noted in Section 3.5 above, the IRS asserts that PBI's $312 million PCT payment in 2012 undervalued the pre-existing IP by approximately $540 million. Because the 2012 taxable year is outside the current examination, the IRS has sought to achieve the economic equivalent of a PCT adjustment by increasing PBI's cost-sharing percentages for TY 2017–2020. This approach conflates two distinct transfer pricing issues: the one-time valuation of pre-existing IP at the inception of the CSA (the PCT issue) and the ongoing allocation of intangible development costs between CSA participants (the RAB-based cost-sharing ratio issue). Even if the IRS were correct that the PCT was undervalued — which PPC disputes, as set forth in Section IV.5 below — the appropriate remedy would be an adjustment to the PCT payment itself, not an inflation of the ongoing cost-sharing ratios. The regulations draw a clear distinction between PCT payments and cost-sharing payments, and the IRS's attempt to blur that distinction should not be sustained.
Third, the IRS's proposed percentages would result in PBI bearing a share of costs that exceeds PBI's share of reasonably anticipated benefits, in violation of the fundamental principle underlying Treas. Reg. § 1.482-7(e). As demonstrated by the Whitmore Valuation Group's economic analysis (summarized in Section IV.4 below), PBI's operating margins under PPC's reported cost-sharing ratios are consistent with those of comparable entities, confirming that the existing cost-sharing allocation produces arm's-length results. The IRS's proposed percentages would depress PBI's returns below arm's-length levels, producing an outcome that is inconsistent with the arm's-length standard.
4.4 Whitmore Valuation Group CPM/TNMM Analysis
PPC engaged Whitmore Valuation Group LLC ("WVG"), an independent economic consulting firm, to prepare a comprehensive economic analysis supporting the arm's-length character of the intercompany arrangements at issue. This engagement was structured under a Kovel arrangement with Calderwood & Harkness LLP (Kovel Letter Reference 1018-00009-KV, dated June 20, 2022) to preserve the protections of the attorney work product doctrine and the attorney-client privilege.
As one component of its analysis, WVG applied the Comparable Profits Method ("CPM"), which corresponds to the Transactional Net Margin Method ("TNMM") under the OECD Transfer Pricing Guidelines, to test the arm's-length character of PBI's operating results under the reported cost-sharing arrangement. The CPM/TNMM analysis compared PBI's operating margins to those of 22 comparable entities identified through a rigorous search and screening process. The comparable set consisted of independent distributors and IP-holding companies operating in the pharmaceutical and biotechnology sectors, selected on the basis of functional and financial comparability criteria consistent with Treas. Reg. § 1.482-5 and the OECD Guidelines.
The results of the CPM/TNMM analysis demonstrated that PBI's operating margins fell within the interquartile range of the comparable set in each of the four Tax Years at Issue (2017–2020). This finding corroborates the arm's-length character of PBI's overall return and, by extension, the reasonableness of the cost-sharing ratio that produced those returns. If PBI's cost-sharing payments had been inflated to the levels proposed by the IRS, PBI's operating margins would have fallen below the lower quartile of the comparable range in multiple years, indicating that the IRS's proposed ratios would produce results inconsistent with the arm's-length standard.
A summary of the WVG CPM/TNMM analysis, including the identification of comparable companies, the comparability screening methodology, and the interquartile range results, will be attached as Exhibit C.
4.5 PCT Valuation Supports Cost-Sharing Ratios
As an additional component of its analysis, WVG performed an income method / Discounted cash flow ("DCF") valuation of the PCT to test the arm's-length character of the $312 million PCT payment made by PBI to PPC on July 1, 2012. The DCF analysis was conducted under the direction of Dr. Helena Vasquez, Managing Director of WVG, and Dr. Rohan Chakrabarti, Senior Director of WVG, both of whom are experienced transfer pricing economists with extensive expertise in pharmaceutical IP valuation.
The WVG DCF analysis employed updated revenue projections and a weighted average cost of capital ("WACC") discount rate of 9.8%, which was derived from a detailed analysis of pharmaceutical-industry cost of capital data, including comparable company betas, equity risk premiums, size premiums, and debt-to-equity ratios. The 9.8% WACC reflects the risk characteristics of the pharmaceutical IP portfolio contributed to the CSA, including the inherent uncertainties associated with pharmaceutical development, regulatory approvals, and commercial launch in international markets.
Based on this analysis, WVG concluded that the arm's-length range for the PCT payment was $278 million to $361 million. The $312 million PCT payment actually made by PBI falls comfortably within this range, confirming that the PCT was properly valued at the time of the CSA's inception.
The IRS's valuation of the PCT at $852 million was based on a WACC of 7.2%, which is materially lower than the rate supported by the available market data. A discount rate of 7.2% underestimates the risk associated with pharmaceutical IP development and commercialization and produces an inflated present value of projected cash flows. Dr. Vasquez's detailed discount rate analysis demonstrates that the IRS's 7.2% WACC is below the range observed for comparable pharmaceutical companies and does not appropriately reflect the risk premiums, beta comparables, and industry-specific cost of capital considerations that are standard in pharmaceutical IP valuation. The difference between the IRS's 7.2% WACC and WVG's 9.8% WACC accounts for a substantial portion of the divergence in PCT valuations.
V. LAW AND ARGUMENT — LEGACY IP ROYALTY RATE
5.1 Legal Framework
Treasury Regulation § 1.482-4 provides the methods for determining the arm's-length amount charged in a controlled transaction involving the transfer or use of intangible property. The specified methods include the comparable uncontrolled transaction ("CUT") method, the comparable profits method, and the profit split method, among others.
The CUT method, set forth in Treas. Reg. § 1.482-4(c), evaluates the arm's-length royalty for a controlled transfer of intangible property by reference to the royalty rate charged in comparable uncontrolled transactions. The reliability of the CUT method depends on the degree of comparability between the controlled and uncontrolled transactions. Treas. Reg. § 1.482-4(c)(2) identifies the following comparability factors relevant to the application of the CUT method:
(a) The type and nature of the intangible property;
(b) The contractual terms of the license (including exclusivity, geographic scope, duration, and termination provisions);
(c) The economic conditions existing during the period of the license;
(d) The functional analysis of the parties (including functions performed, risks assumed, and resources employed); and
(e) The property or services provided in connection with the license.
Where differences between the controlled and uncontrolled transactions exist, the CUT method requires that appropriate comparability adjustments be made to account for such differences. See Treas. Reg. § 1.482-4(c)(2)(ii). If reliable adjustments cannot be made, the reliability of the CUT analysis is reduced, and alternative methods may produce a more reliable result under the best method rule.
The best method rule of Treas. Reg. § 1.482-1(d) requires that the method selected be the one that, under the facts and circumstances, provides the most reliable measure of an arm's-length result. The selection of the best method depends on the degree of comparability between the controlled transaction and any uncontrolled transactions, the quality of the data and assumptions relied upon, and the sensitivity of the results to deficiencies in the data.
In Harborview Corporation, Inc. v. Commissioner, the Eighth Circuit emphasized the importance of proper application of the CUT methodology and the need for reliable comparable data. 900 F.3d 610 (8th Cir. 2018). The court noted that the CUT method can be reliable when properly applied, but that comparability deficiencies must be addressed through appropriate adjustments. The Eighth Circuit's remand in Harborview Corporation underscores that the selection of CUT comparables and the adjustments applied to those comparables are critical to the reliability of the analysis.
5.2 PPC's 4.5% Royalty Rate Is Within the Arm's-Length Range
PPC's 4.5% royalty rate for the legacy IP license was established through a CUT analysis performed by Crestfield & Associates as part of PPC's contemporaneous transfer pricing documentation, and subsequently validated and supplemented by Whitmore Valuation Group's independent economic analysis.
The WVG CUT analysis identified 14 comparable uncontrolled pharmaceutical license agreements through a comprehensive search of publicly available licensing databases and SEC filings. The comparable agreements were selected on the basis of the comparability factors prescribed by Treas. Reg. § 1.482-4(c), including similarity in therapeutic area, stage of product development, geographic scope, exclusivity terms, and functional risk allocation. Appropriate comparability adjustments were applied where necessary to account for differences between the comparable agreements and the controlled PPC-PBI legacy IP license.
The results of the WVG CUT analysis are as follows:
• Interquartile range of royalty rates: 3.1% to 6.8%
• Median royalty rate: 4.4%
PPC's 4.5% royalty rate falls squarely within the interquartile range of the properly identified comparable agreements and is nearly identical to the median rate of 4.4%. Under the arm's-length standard, a controlled transaction result that falls within the interquartile range of comparable uncontrolled transactions is generally accepted as arm's-length. See Treas. Reg. § 1.482-1(e)(2)(iii)(B). PPC's royalty rate is therefore within the arm's-length range, and no adjustment is warranted.
5.3 Rebuttal of IRS's Proposed 11.0% Royalty Rate
The IRS proposes to increase the legacy IP royalty rate from 4.5% to 11.0%, an increase of 6.5 percentage points. This proposed rate is based on a CUT analysis performed by IRS Economist Dr. Alan Washburne using a different set of comparable uncontrolled transactions than those identified in PPC's and WVG's analyses. PPC contends that the IRS's proposed 11.0% rate is not supported by reliable CUT analysis and should be rejected for the following reasons.
First, the IRS's selected CUT comparables include agreements with materially different characteristics from the PPC-PBI legacy IP license. Among the deficiencies in the IRS's comparable set are agreements involving different therapeutic areas (e.g., cardiovascular and central nervous system compounds, as opposed to the oncology, immunology, and rare-disease compounds at issue), different stages of development (e.g., early-stage clinical compounds with high uncertainty, as opposed to PPC's mature, approved legacy compounds), different geographic scope (e.g., global licenses, as opposed to the non-Americas territory license at issue), and different risk allocation (e.g., agreements in which the licensee bore development risk, as opposed to the PBI arrangement where the licensed compounds were already approved and commercialized). These material differences undermine the reliability of the IRS's CUT analysis and render the proposed 11.0% rate unreliable as a measure of arm's-length pricing.
Second, the IRS failed to make appropriate comparability adjustments to account for the differences between its selected CUT comparables and the controlled transaction, as required by Treas. Reg. § 1.482-4(c)(2). The regulations expressly provide that if differences between the controlled and uncontrolled transactions would materially affect the royalty rate, adjustments must be made to eliminate those differences. The IRS's failure to make such adjustments — or its inability to do so reliably — renders its CUT analysis deficient under the standards of the applicable regulations.
Third, the IRS's proposed 11.0% royalty rate significantly exceeds the upper quartile (6.8%) of the properly identified comparable agreements in the WVG CUT analysis. The 11.0% rate is more than 60% above the upper quartile boundary of the arm's-length range established by the WVG analysis and is nearly 2.5 times the median rate of 4.4%. This dramatic deviation from the properly determined interquartile range strongly suggests that the IRS's comparable set is not sufficiently comparable to the controlled transaction and that the IRS's proposed rate does not satisfy the best method rule.
Fourth, the IRS's CUT selection does not satisfy the best method rule of Treas. Reg. § 1.482-1(d). Given the substantial comparability deficiencies in the IRS's selected agreements, PPC submits that the WVG CUT analysis — which identified comparables with a higher degree of similarity to the controlled transaction and applied appropriate comparability adjustments — provides a more reliable measure of the arm's-length royalty rate.
5.4 Declining Legacy Product Sales Confirm Appropriateness of 4.5%
The appropriateness of PPC's 4.5% royalty rate is further confirmed by the declining trajectory of the legacy compound sales during the Tax Years at Issue. Non-Americas net sales of the legacy compounds declined from $814.6 million in 2017 to $624.1 million in 2020 — a decline of approximately 23% over a four-year period. This decline reflects the normal product lifecycle dynamics affecting mature pharmaceutical compounds, including loss of patent exclusivity in certain markets, increasing generic competition, market share erosion, and reduced promotional support.
The declining revenue base for these aging compounds is a significant comparability factor that supports a lower royalty rate. In third-party pharmaceutical licensing, royalty rates for mature, declining-revenue compounds are typically lower than royalty rates for compounds at the peak of their commercial potential, precisely because the licensee's anticipated economic benefits are diminishing. The IRS's proposed increase to an 11.0% royalty rate moves in the opposite direction — imposing a higher rate at a time when the value of the underlying IP is declining — and is economically irrational.
PPC's 4.5% rate appropriately reflects the diminishing value of the underlying legacy IP during TY 2017–2020, and is consistent with the arm's-length standard.
VI. LAW AND ARGUMENT — PBI ECONOMIC SUBSTANCE AND DEMPE FUNCTIONS
6.1 Legal Framework
The economic substance doctrine is a judicially developed principle that, in the transfer pricing context, requires that entities claiming income from or bearing costs related to intangible property have genuine substance commensurate with their claimed economic role. While IRC § 7701(o) codified the economic substance doctrine for certain purposes, the doctrine's application in the transfer pricing context is also informed by the functional analysis requirements of Treas. Reg. § 1.482-1(d)(3), which requires consideration of the functions performed, risks assumed, and resources employed by the parties to a controlled transaction.
The OECD Transfer Pricing Guidelines, Chapter VI (Intangibles), articulate the DEMPE framework, which identifies five categories of functions relevant to the creation and exploitation of intangible property:
(a) Development: Activities contributing to the creation or improvement of intangible property, including research and development, clinical trials, and related scientific activities;
(b) Enhancement: Activities that increase the value of existing intangible property, including product improvements, formulation modifications, label extensions, and market-specific adaptations;
(c) Maintenance: Activities that preserve the value of intangible property, including maintenance of regulatory approvals, quality control, pharmacovigilance, and post-marketing surveillance;
(d) Protection: Activities that protect the intangible property from infringement or misappropriation, including patent prosecution, trademark enforcement, litigation management, and regulatory data exclusivity protection; and
(e) Exploitation: Activities that generate economic value from the intangible property, including commercialization, marketing, pricing, distribution, and market access activities.
Under both the Treasury Regulations and the OECD Guidelines, the allocation of income from intangibles must be consistent with the substance of the arrangement — that is, income should be attributed to the entity that performs the DEMPE functions, assumes the associated risks, and employs the resources necessary to perform those functions and manage those risks. See Treas. Reg. § 1.482-1(d)(3); OECD Transfer Pricing Guidelines, ¶¶ 6.32–6.71.
Case law in the transfer pricing area has similarly emphasized the importance of genuine substance in the context of foreign IP-holding entities. Courts have scrutinized whether foreign entities are mere conduits for the allocation of income to low-tax jurisdictions or, alternatively, whether they possess the personnel, assets, and decision-making authority commensurate with their claimed economic role.
6.2 PBI Possesses Robust Economic Substance
PBI is a substantial operating entity with genuine economic substance, not a shell holding company or a mere conduit for income allocation. The evidence of PBI's economic substance is extensive and will be documented in detail in Exhibit D. The key indicators of PBI's substance include the following:
Personnel: As of the end of fiscal year 2020, PBI employed 185 individuals in Dublin, Ireland, having grown from 52 employees at the time of its establishment in 2012. PBI's workforce includes professionals in regulatory affairs, medical affairs, commercial strategy, supply chain management, finance, legal, and general administration. These employees are not nominal or part-time; they are full-time professionals engaged in the day-to-day management and operation of PBI's business.
Management and Governance: PBI's Managing Director, Aidan Naughton, is resident in Dublin, Ireland, and exercises operational authority over PBI's business activities. Mr. Naughton has served in this role since PBI's inception and has been the primary decision-maker for PBI's commercial operations throughout the Tax Years at Issue. During TY 2017–2020, PBI's board of directors held a total of 42 meetings in Dublin (consisting of quarterly meetings plus special sessions), at which the board addressed matters of commercial strategy, pricing, product launches, regulatory submissions, distribution partner appointments, and capital allocation. The frequency and substance of these board meetings demonstrate that PBI's governance is active and meaningful.